Galderma Initiates Two New Clinical Trials Investigating Nemolizumab in Patients With Systemic Sclerosis and Chronic Pruritus of Unknown Origin
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced the initiation of two new clinical trials to investigate the efficacy and safety of nemolizumab in treating patients living with Systemic Sclerosis (SSc) and Chronic Pruritus of Unknown Origin (CPUO) – two chronic conditions with high unmet need. 1-3,7
Nemolizumab is a monoclonal antibody that specifically targets the IL-31 receptor alpha, inhibiting the signaling of IL-31, a neuroimmune cytokine that plays a role in driving itch – the main symptom of CPUO – and inflammation and fibrosis, which are hallmarks of SSc. 1,3,4
'Investigating nemolizumab in two new trials in Systemic Sclerosis and Chronic Pruritus of Unknown Origin, both of which are associated with poor patient outcomes and low quality of life, underscores our commitment to addressing skin conditions with high unmet needs. These trials may help us better understand these complex diseases and offer hope for patients seeking relief from these severe and potentially life-threatening conditions.'
BALDO SCASSELLATI SFORZOLINI, M.D., PH.D.
GLOBAL HEAD OF R&D
GALDERMA
Systemic Sclerosis (SSc)
SSc is a rare, potentially fatal autoimmune disease that causes inflammation and fibrosis (hardening) of the skin and internal organs. 1 It most commonly affects women between the ages of 30 and 50 years old, often leading to a lower quality of life and a much higher risk of death compared to healthy people of the same age. 2,8 Currently, there are no approved therapies that address the disease as a whole, highlighting the urgent need for effective treatments. 1,2,8
Galderma's phase II proof-of-concept study is a multicenter, randomized, double-blind, placebo-controlled study investigating the pharmacokinetics and pharmacodynamics of nemolizumab in adults with SSc. Patient enrollment is planned to begin in H2 2025, with completion anticipated in 2028. This trial represents a significant step towards addressing the remaining unmet treatment needs in SSc and demonstrates Galderma's commitment to driving progress for patients living with this disease.
The study was designed in collaboration with a Steering Committee of world-leading rheumatology and dermatology experts, including lead trial investigator, Professor Oliver Distler, M.D., Zürich, Switzerland; Professor Dinesh Khanna, M.D., Director of the Scleroderma Program, University of Michigan, United States (U.S.); Professor Robert Spiera, M.D., Director of the Scleroderma, Vasculitis and Myositis Center, Hospital for Special Surgery, New York, U.S.; and Professor Johann Gudjonsson, M.D., PhD, Dermatologist, University Hospital Michigan, U.S.
The trial is expected to be conducted in several countries in North America, Europe and South America. More information about the study will be made available soon on the clinicaltrials.gov website.
'Systemic Sclerosis can have a profound impact on both the quality and length of a person's life. It causes the skin to harden, damages blood vessels, leads to joint pain, and can result in serious fibrosis in multiple internal organs, sometimes with life-threatening consequences. With no currently approved treatments that are indicated to treat the several symptoms this autoimmune disease presents, I look forward to investigating the role that nemolizumab could potentially play in this condition.'
PROFESSOR OLIVER DISTLER, M.D.
LEAD INVESTIGATOR: SYSTEMIC SCLEROSIS PHASE II STUDY
ZÜRICH, SWITZERLAND
Chronic Pruritus of Unknown Origin (CPUO)
CPUO is an underdiagnosed condition defined as itch lasting for more than six weeks without an identified cause and mostly affects the elderly. 3 The chronic and persistent itch is often described as being as debilitating as chronic pain, leading to reduced quality of life and affecting sleep patterns and mood. 3,7 There are currently no approved treatments for this condition. 3
Galderma's new phase II CPUO trial reinforces the company's commitment to exploring options for patients with chronic skin conditions that significantly impact quality of life. This randomized, double-blind, placebo-controlled proof-of-concept study will explore the pharmacokinetics and pharmacodynamics of nemolizumab in adults. Enrollment is expected to start in H2 2025 in the U.S., with completion anticipated in 2026. The study was designed in collaboration with a Steering Committee of world-leading dermatology experts, including the lead investigator Dr. Shawn Kwatra, M.D., PhD., Joseph W. Burnett Endowed Professor, Chairman of Dermatology, University of Maryland School of Medicine, U.S., and Dr. Sarina Elmariah, MD, PhD, MPH, Associate Professor and Dermatology Director at the Center for Itch and Neurosensory Disorders at the University of California in San Francisco, U.S.
The study is being conducted in the U.S. and more information about the study will be made available soon on the clinicaltrials.gov website.
'It is challenging to treat Chronic Pruritus of Unknown Origin as physicians have limited therapeutic options specifically targeting the underlying cause of itch. With the extensive data showing that IL-31 is a key driver of itch, I'm excited to explore whether nemolizumab's inhibition of IL-31 signaling might effectively reduce the intractable itch experienced by patients with Chronic Pruritus of Unknown Origin.'
DOCTOR SHAWN KWATRA, M.D., PHD
LEAD INVESTIGATOR, CHRONIC PRURITUS OF UNKNOWN ORIGIN PHASE II STUDY
JOSEPH W. BURNETT ENDOWED PROFESSOR
CHAIRMAN OF DERMATOLOGY, UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE, U.S.
About nemolizumab
Nemolizumab was approved in August 2024 by the U.S. Food and Drug Administration (U.S. FDA) for the treatment of adults with prurigo nodularis. 5 In December 2024, it was also approved by the U.S. FDA for the treatment of patients 12 years and older with moderate-to-severe atopic dermatitis, in combination with topical corticosteroids and/or calcineurin inhibitors when the disease is not adequately controlled with topical prescription therapies. 5 To date, nemolizumab is approved for both moderate-to-severe atopic dermatitis and prurigo nodularis by multiple regulatory authorities around the world, including in the European Union, Australia, Singapore, Switzerland and the United Kingdom. Additional regulatory submissions and reviews are ongoing.
Nemolizumab was initially developed by Chugai Pharmaceutical Co., Ltd. In 2016, Galderma obtained exclusive rights to the development and marketing of nemolizumab worldwide, except in Japan. In Japan, nemolizumab is marketed as Mitchga ® and is approved for the treatment of prurigo nodularis, as well as pruritus associated with atopic dermatitis in pediatric, adolescent, and adult patients. 9,10
About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body's largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com . References
1. Jimenez SA, Mendoza FA, Piera-Velasquez S. A review of recent studies on the pathogenesis of Systemic Sclerosis: focus on fibrosis pathways. Front Immunol . 2025;16: 1551911. doi: 10.3389/fimmu.2025.1551911
2. Truchetet ME, et al. Current Concepts on the Pathogenesis of Systemic Sclerosis. Clin Rev Allergy Immunol . 2021;64(3): 262–283. doi: 10.1007/s12016-021-08889-8
3. Teresa J, et al. Therapeutics in chronic pruritus of unknown origin. Itch . 2023;8(1): pe64. doi: 10.1097/itx.0000000000000064
4. Silverberg JI, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol . 2020;145(1): 173-182. doi: 10.1016/j.jaci.2019.08.013
5. Nemluvio ® U.S. Prescribing Information. Available online . Accessed June 2025
6. Nemluvio ® European Medicines Agency. Summary of Product Characteristics. Available online . Accessed June 2025
7. Andrade E, et al. Interventions for chronic pruritus of unknown origin. CDSR . 2020;1(1): CD013128. doi: 10.1002/14651858.CD013128.pub2
8. Scleroderma & Systemic Sclerosis. National Health Service. Available online . Accessed June 2025
9. Chugai Pharmaceutical Co., Ltd. Maruho Obtained Regulatory Approval for Mitchga, the first Antibody Targeting IL-31 for Itching Associated with Atopic Dermatitis. Available online . Accessed June 2025
10. Chugai Pharmaceutical Co., Ltd. Mitchga Approved for Itching in Pediatric Atopic Dermatitis and Prurigo Nodularis, for its Subcutaneous Injection 30mg Vials. Available online . Accessed June 2025
View source version on businesswire.com: https://www.businesswire.com/news/home/20250624095800/en/
CONTACT: For further information:
Christian Marcoux, M.Sc.
Chief Communications Officer
[email protected]
+41 76 315 26 50
Richard Harbinson
Corporate Communications Director
[email protected]
+41 76 210 60 62
Céline Buguet
Franchises and R&D Communications Director
[email protected]
+41 76 249 90 87
Emil Ivanov
Head of Strategy, Investor Relations, and ESG
[email protected]
+41 21 642 78 12
Jessica Cohen
Investor Relations and Strategy Director
[email protected]
+41 21 642 76 43
KEYWORD: SWITZERLAND EUROPE
INDUSTRY KEYWORD: HEALTH OTHER HEALTH CLINICAL TRIALS RESEARCH SCIENCE PHARMACEUTICAL BIOTECHNOLOGY
SOURCE: Galderma
Copyright Business Wire 2025.
PUB: 06/25/2025 01:00 AM/DISC: 06/25/2025 01:01 AM
http://www.businesswire.com/news/home/20250624095800/en
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
24 minutes ago
- Medscape
Common Phthalate Tied to Coronary Risk in Car Plant Workers
TOPLINE: Exposure to monoethyl phthalate (MEP) — a chemical commonly found in industrial and personal care products — was associated with a substantially elevated risk for subclinical coronary atherosclerosis among men working in a car assembly unit. METHODOLOGY: Researchers conducted a cross-sectional study to assess whether urinary phthalates showed any association with subclinical coronary atherosclerosis. They included 1119 Spanish male workers (mean age, 50.9 years) from a car assembly plant. A total of 11 urinary phthalate metabolites were measured using liquid chromatography coupled to tandem mass spectrometry. Participants underwent CT scans between January 2011 and December 2014 to determine coronary artery calcium; subclinical coronary atherosclerosis was defined as a coronary artery calcium score ≥ 100 Agatston units. TAKEAWAY: Subclinical coronary atherosclerosis was identified in 114 men (10.2%). MEP was the phthalate with the highest median concentration; men with subclinical coronary atherosclerosis had a higher median MEP concentration than those without the condition (126.1 vs 99.3 µg/g creatinine). Each 1-unit increase in the natural logarithm of MEP was associated with a 21% higher prevalence of subclinical coronary atherosclerosis (adjusted odds ratio, 1.21; 95% CI, 1.02-1.44). Monoisobutyl phthalate and mono-n-butyl phthalate showed a positive association with the condition, but this association did not reach statistical significance. IN PRACTICE: "Educational strategies might complement cardiovascular prevention by promoting behaviors that reduce phthalate exposure, such as choosing fragrance-free products, preferring glass containers over plastics, and minimizing ultraprocessed food consumption," the researchers noted. SOURCE: This study was led by Diana María Mérida, Universidad Autónoma de Madrid, Madrid, Spain. It was published online on August 06, 2025, in The American Journal of Preventive Cardiology. LIMITATIONS: This cross-sectional study could not imply whether phthalates caused subclinical coronary atherosclerosis. The findings may not be generalisable to women, older adults, or individuals from different occupational backgrounds or socioeconomic groups. Urinary concentrations of phthalate metabolites reflect only short-term exposure, but chronic diseases are usually linked to long-term exposures. DISCLOSURES: This study was supported by the Health Research Fund from the State Secretary of R+D and FEDER/FSE, Instituto de Salud Carlos III, Spain. The authors reported having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
24 minutes ago
- Medscape
Erectile Function After Prostate Radiation: How MRI May Help
TOPLINE: Among patients with prostate cancer who received MRI-guided stereotactic body radiation therapy (SABR), more than 80% demonstrated 'classic' neurovascular bundle patterns and over 96% showed more than 1-cm separation of internal pudendal arteries from the prostate. These findings indicated that most patients have favorable anatomic patterns that would allow radiation oncologists to minimize radiation to structures involved in erectile function and help reduce patients' risk for posttreatment erectile dysfunction. METHODOLOGY: Erectile dysfunction is a common side effect for men with prostate cancer who undergo SABR. Radiation-related damage to critical nearby structures, such as the neurovascular bundles and internal pudendal arteries, likely contributes to this issue. Identifying these structures on MRI during radiation planning can minimize exposure during SABR and reduce the risk for erectile dysfunction. Researchers analyzed 160 consecutive patients with prostate cancer (median age, 70 years) who underwent MRI-linear accelerator-based SABR between January and December 2024. Based on the MRI scans, researchers classified neurovascular bundle patterns into classic (discrete), adherent (dispersed and adherent to the prostatic capsule), or absent. Researchers also measured the shortest distance between internal pudendal arteries to the prostate capsule and the membranous urethral length and compared imaging features by prostate volumes, Prostate Imaging Reporting and Data System (PI-RADS) scores, lesion locations, and Gleason grade group. TAKEAWAY: The classic neurovascular bundle pattern was the most common, present in 80% of right-sided and 85% of left-sided evaluations, while adherent neurovascular bundles were less common, observed in 18.1% of right-sided and 13.8% of left-sided scans. The median shortest distance between internal pudendal arteries and the prostate capsule was 2.3 cm on both sides, with only 3.1% (left side) to 3.8% (right side) of patients having a distance less than 1.0 cm. The median membranous urethral length was 1.5 cm, with only 2.5% of men having one shorter than 1.0 cm. Researchers found no significant association between these MRI features and prostate volumes of greater or less than 40 mL, PI-RADS scores, zonal location of the dominant intraprostatic lesion, and Gleason grade on pathology. IN PRACTICE: 'Most patients with prostate cancer undergoing SABR demonstrated favorable anatomy of the critical structures, potentially important for potency preservation,' the authors wrote, reflecting on the fact that real-time adaptive planning, especially with MRI-guided radiotherapy, has potential for helping 'identify, define, and effectively dose-constrain these critical structures.' SOURCE: The study, led by Sungmin Woo, MD, PhD, NYU Grossman School of Medicine in New York City, was published online in Practical Radiation Oncology. LIMITATIONS: The study was conducted at a single institution, which may limit the generalizability of the findings. Additionally, the analysis excluded patients with prior prostate-directed treatments, artifacts on MRI scans, and extraprostatic extension or those without diagnostic multiparametric MRI scans, restricting applicability to patients with more advanced disease or suboptimal imaging. DISCLOSURES: This study did not receive any specific funding. One author disclosed serving as a consultant for Boston Scientific. The other authors declared having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
24 minutes ago
- Medscape
Can Use of Psychotropic Drugs Signal Autoimmune Addison?
TOPLINE: Patients with autoimmune Addison disease (AAD) showed increased use of hypnotics/sedatives, anxiolytics, and antidepressants in the year before diagnosis, suggesting potential misdiagnosis of early symptoms. The elevated use of hypnotics/sedatives persisted for years after diagnosis, indicating persistent sleep disturbances in this population. METHODOLOGY: Researchers in Sweden conducted a population-based cohort study to assess the use of psychotropic drugs among patients with AAD (n = 963; median age at diagnosis, 40.8 years; 57.9% women) and matched control individuals from the general population (n = 9366). The outcome was at least one annual dispensation of antipsychotics, anxiolytics, hypnotics/sedatives, and/or antidepressants from 3 years before to 3 years after the diagnosis of AAD, covering the period from July 2006 through December 2019. A cross-sectional analysis of data from 2019 was conducted to examine the chronic use of psychotropic drugs, requiring two or more prescriptions of any drug class among patients diagnosed with AAD between 2006 and 2018. TAKEAWAY: Hypnotics/sedatives were the most dispensed psychotropic medications, with 14.2% of patients receiving them 1 year post-diagnosis, whereas antipsychotics were the least dispensed drugs. In the year before diagnosis, patients with AAD had higher odds of using hypnotics/sedatives (odds ratio [OR], 1.72; P < .001), anxiolytics (OR, 1.38; P = .014), and antidepressants (OR, 1.29; P = .016) than control individuals. The use of hypnotics/sedatives remained elevated for years after diagnosis among patients with AAD vs control individuals, and this trend persisted in the cross-sectional analysis. IN PRACTICE: "[These] findings underscore the importance to considering somatic differential diagnoses, such as adrenal insufficiency, when a person presents with symptoms like fatigue or melancholy. Conversely, it is equally important to evaluate potential psychiatric causes in individuals with adrenal insufficiency who report excessive fatigue or melancholy," the authors wrote. SOURCE: This study was led by Sara Öster, Karolinska Institutet, Stockholm, Sweden. It was published online on August 02, 2025, in European Journal of Endocrinology. LIMITATIONS: Medication dispensations might not have reflected actual patterns of drug use. The study did not analyse prescribed daily doses, focusing instead on the annual prevalence of drug use. DISCLOSURES: This study was supported by the Centre for Clinical Research and Education, the Region Värmland County Council, and a Regional Agreement on Medical Training and Clinical Research between Stockholm County Council and Karolinska Institutet. The authors reported having no competing interests. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
